Favipiravir is a broad spectrum antiviral drug that may be used to treat influenza. Previous 12 research has identified that favipiravir likely acts as a mutagen but the precise mutation bias 13 that favipiravir induces in influenza virus RNAs has not been described. Here, we use next-14 generation sequencing (NGS) with barcoding of individual RNA molecules to accurately and 15 quantitatively detect favipiravir-induced mutations and to sample orders of magnitude 16 more mutations than would be possible through Sanger sequencing. We demonstrate that 17 favipiravir causes mutations and show that favipiravir primarily acts as a guanine analogue 18 and secondarily as an adenine analogue resulting in the accumulation of transition 19 mutations. We also use a standard NGS pipeline to show that the mutagenic effect of 20 favipiravir can be measured by whole genome sequencing of virus.
Abstract 11 Favipiravir is a broad spectrum antiviral drug that may be used to treat influenza. Previous 12 research has identified that favipiravir likely acts as a mutagen but the precise mutation bias 13 that favipiravir induces in influenza virus RNAs has not been described. Here, we use next- 14 generation sequencing (NGS) with barcoding of individual RNA molecules to accurately and 15 quantitatively detect favipiravir-induced mutations and to sample orders of magnitude 16 more mutations than would be possible through Sanger sequencing. We demonstrate that 17 favipiravir causes mutations and show that favipiravir primarily acts as a guanine analogue 18 and secondarily as an adenine analogue resulting in the accumulation of transition 19 mutations. We also use a standard NGS pipeline to show that the mutagenic effect of 20 favipiravir can be measured by whole genome sequencing of virus. 21 Importance 22 New antiviral drugs are needed as a first line of defence in the event of a novel influenza 23 pandemic. Favipiravir is a broad-spectrum antiviral which is effective against influenza. The 24 exact mechanism of how favipiravir works to inhibit influenza is still unclear. We used next- 25 generation sequencing (NGS) to demonstrate that favipiravir causes mutations in influenza 26 RNA. The greater depth of NGS sequence information over traditional sequencing methods 27 allowed us to precisely determine the bias of particular mutations caused by favipiravir. NGS 28 can also be used in a standard diagnostic pipeline to show that favipiravir is acting on the 29 virus by revealing the mutation bias pattern typical to the drug. Our work will aid in testing 30 whether viruses are resistant to favipiravir and may help demonstrate the effect of Introduction 36 Influenza virus is responsible for the deaths of between 290,000-650,000 people 37 globally each year 1 . The emergence of a novel strain of influenza in humans could lead to an 38 influenza pandemic with significant mortality worldwide 2 . Whilst vaccination provides good 39 levels of protection against seasonal influenza, at the start of a pandemic, antiviral drugs 40 would be the frontline of defence during a period of development of a specific vaccine 3 . 41 Historically, there have been only two licensed classes of antiviral drug for influenza: 42 adamantanes and Neuraminidase inhibitors (NAIs). Adamantanes are no longer in clinical 43 use as almost all circulating viruses are resistant 4,5 . Furthermore, some previous seasonal 44 viruses have shown high levels of resistance to the most commonly administered NAI, 45 oseltamivir 6 and oseltamivir resistant A(H7N9) viruses with pandemic potential have 46 emerged and are transmissible between ferrets 7-9 . New drugs are needed for treatment of 47 seasonal influenza as well as for pandemic preparedness and a number of drug classes are 48 under development including compounds that target the viral RNA dependent RNA 49 polymerase (RdRP) 10 . In 2014, Favipiravir, an antiviral drug developed by Toyama, was 50 licensed for use in Japan against emerging influenza viruses that exhibit resistance to other 51 antivirals 11 . However, the exact mechanism through which favipiravir exerts an antiviral 52 effect on influenza is unclear. An increased knowledge of the mechanism of action of 53 favipiravir could be useful in determining whether specific viruses are less susceptible and 54 evaluating the potential for emergence and transmission of resistant viruses. 55 Favipiravir is a nucleoside analogue that is active against all subtypes of influenza 56 and has shown a potent antiviral effect both in vitro and in vivo [12] [13] [14] [15] [16] [17] . Favipiravir has 57 completed a phase III clinical trial in Japan and has undergone a phase III trial in the USA 18 .
Favipiravir has also been shown to be active in vitro and in animal models against a wide 59 range of RNA viruses, some for which there are no licensed drugs as a treatment option [18] [19] [20] [21] [22] [23] [24] [25] . 60 There is strong evidence that favipiravir acts as a mutagen by incorporating into both 61 positive and negative stranded RNA and being aberrantly copied as multiple bases 15, [26] [27] [28] [29] [30] . 62 This is thought to be a different mechanism of action from ribavirin, another broadly acting 63 nucleoside analogue that has been used previously to treat influenza 26, 31 . Studies have 64 shown that favipiravir competes against guanine and adenine to be incorporated into RNA 65 and is non-competitive against cytosine and uracil 30,32-34 . This would suggest that favipiravir following a passaging experiment and showed an increase in Shannon entropy using next-72 generation sequencing (NGS) 35 . However, in contrast to studies using Sanger sequencing, 73 Marathe et al. reported a slight bias towards transversions in influenza infected mice 74 treated with favipiravir using NGS 36 . Studies with other viruses have given mutation patterns 75 which suggest that favipiravir acts as a purine analogue 28,29,37,38 . Interestingly, several 76 studies with favipiravir and influenza have suggested that favipiravir acts not as a mutagen 77 but as a chain terminator preventing the extension of the RNA strand following 78 incorporation 32,33 . A primer extension study suggested that the block could occur with a 79 single molecule of favipiravir 32 but other studies have suggested that chain termination 80 occurs following the incorporation of two molecules of favipiravir 30, 33, 34 . 81 In this study, we used next generation sequencing to determine the mutation bias of 82 favipiravir on influenza virus RNAs. We employed two methods of analysis: the first method 83 uses Primer ID which is a technique for labelling each individual RNA molecule with a 84 barcode to account for PCR and sequencing errors 39-41 . This technique can very precisely 85 uncover the mutation bias by analysing small, targeted areas of the genome. The second 86 method developed a novel analysis of data obtained from a standard sequencing pipeline as 87 would be found in many National Influenza Centres or public health laboratories. This 88 showed the mutation bias induced by drug treatment over the whole genome was similar to 89 that detected using the precise Primer ID methodology and confirmed that the effect of 90 favipiravir could be readily measured using NGS from a standard sequencing pipeline. to retain reads with a median phred score of 20 and minimum read length of 250bp. Intact 127 barcode sequences were extracted from the read pairs; any sequences without a fully 128 formed barcode or with errors in the internal Ts of the barcode were discarded. Consensus 129 sequences were generated for each barcode that had more than three reads with the 130 consensus taken as the majority of the reads. Samples for which there was no majority read 131 were discarded as potentially this could be an example of two RNA sequences having the 132 same barcode 43 . The consensus sequences were mapped and compared to the Vic75 133 reference and any variants were extracted. We subsequently decided to use a more 134 stringent cut-off of four reads per barcode to minimize errors caused by barcodes with a low 135 number of reads. We present all our sequencing results as mutations in positive orientation 136 as would have been seen in the mRNA. 
Results

180
Primer ID allows calculation of mutation bias and relative mutation rate 181 In order to determine the mutagenic effect of favipiravir, we employed next generation 182 sequencing using Primer ID to analyse the products of a minigenome assay 46 , which allowed 183 for the unbiased measurement of mutations ( Figure 1 ). When sequencing virus, particularly 184 over several rounds of replication, a proportion of possible mutations will not be measured 185 as they would cause too large a fitness cost to the virus and thus will not be amplified. To 186 avoid this scenario, we sequenced the reporter gene from the minigenome assay as the 187 reporter protein has no effect on further RNA accumulation. Thus, this strategy should Figure 2B ). At 100 µM favipiravir, there was a significant reduction in mRNA 207 (P<0.0001). This suggested that at doses up to 50 µM, the inhibitory effect of favipiravir in 208 the minigenome assay was caused by mutagenesis and not through chain termination, 209 which could have played a role at the highest dose of drug. 210 In order to test how favipiravir affected the mutation rate of the reconstituted viral 211 polymerase, we sequenced the positive stranded H3 HA RNAs. As each individual barcode 212 represents a single RNA molecule, we calculated consensus sequences for each barcode. 213 Mutations which did not appear in a majority of reads were ascribed to PCR or sequencing 214 error and removed from further analyses. In total, we analysed 6,623 substitutions in 215 ~6,900,000 bases of sequencing data. Figure 2C shows the number of mutations per 10,000 216 nucleotides above the baseline (0 µM favipiravir) for each sample. As the concentration of 217 favipiravir increased, the number of mutations increased. At the highest concentration of 218 favipiravir tested (100 µM), there would be an additional 15 errors per 10,000 nucleotides 219 on average compared to the control. We varied the cut-off for the number of sequencing 220 reads needed to include a barcode (Supplemental figure 1). The choice of cut-off did not 221 significantly alter the results for values <10 reads. We chose a cut-off of 4 reads per barcode 222 as this removed some errors associated with low numbers of reads per barcode whilst 223 including the majority of the data. 224 We next categorised the mutations identified by sequencing as transitions or transversions, 225 or as the individual base-pair mutations ( Figure 2D , E). Our results confirmed that the main 226 cause of the increase in mutation rate was transition mutations ( Figure 2D ). There was no 227 increase in the rate of transversion mutations as the concentration of favipiravir increased 228 (F-test, F= 0.4593, d.f. 1,4, p=0.5351). Figure 2E shows the increase in the likelihood of 229 different categories of mutations compared to the control. The most common transitions 230 were C->U and G->A mutations that would be induced when favipiravir is acting as a 231 guanine analogue. However, there was also a smaller increase in the reverse transitions 232 from U->C and A->G where favipiravir acts as an adenine analogue. On average, there was 233 an approximately 3.5-fold increase in the rate of C->U or G->A mutations compared to a U-234 >C or A->G mutations.
235
Primer ID sequencing of viruses confirms that favipiravir causes mutations 236 We next tested whether we could use Primer ID to measure the increase in mutation rate of 237 RNAs generated during virus infection. To minimize the loss of viral RNAs that contained 238 mutations rendering the virus nonviable, we infected cells at a high MOI so that there was 239 only a single replication cycle. We first confirmed that favipiravir inhibited influenza under 240 these conditions ( Figure 3A ). There was a greater than 1000-fold reduction in infectious titre 241 of influenza A/Eng195/2009 A(H1N1)pdm09 virus (Eng 195) after 24 hours infection at high 242 concentrations of favipiravir and a 10-fold reduction at 1 µM drug. We extracted RNA from 243 the cells and sequenced the vRNA of RNA segment 2 with appropriate barcoded primers. In 244 total, we analysed ~56,000,000 bases and found 25,441 substitutions. All concentrations of 245 favipiravir showed an increase in mutation rate compared to the no drug control (Figure   246 3B). The mutation rate caused by favipiravir was ~3 fold higher at 10 µM than at 1 µM, but 247 surprisingly, the mutation rate at 100 µM favipiravir was lower than at 10 µM. The increase 248 in mutation rate at all concentrations of favipiravir was almost entirely due to transitions 249 ( Figure 3C ). The mutation bias measured was subtly different than that seen using the 250 minigenome assay with C->U occurring most often but G->A and U->C mutations occurring 251 at comparable rates ( Figure 3D ). This suggests that there was a higher rate of incorporation 252 of favipiravir during negative strand synthesis compared to positive strand synthesis in virus 253 infected cells (see Figure 5 ).
254
Next generation sequencing can reveal mutation bias 255 The experiments with Primer ID showed the mutation rate and bias for a small targeted 256 portion of influenza genome. Next, we wanted to test whether we could measure the 257 mutagenic effect of favipiravir using a standard NGS pipeline typical of those in public health 258 laboratories (Supplemental figure 2). Eng195 virus was propagated at a high MOI for 24 259 hours in the presence of 10 or 100 µM favipiravir. The supernatant was plaqued to confirm 260 that favipiravir had an inhibitory effect on the virus and there was >2 log inhibition at 10 µM 261 and >4 log inhibition at 100 µM. We extracted RNA from virus particles in the supernatant 262 and used next generation sequencing to obtain sequence data from the population of 263 surviving viruses. In order to analyse mutation bias using next generation data, it is 264 necessary to ensure that the mutations used for the analysis are independent so that the 265 same mutation occurring on multiple reads is not counted as multiple mutational events but 266 as a single mutational event. Therefore, we treated each base in the influenza genome 267 independently and recorded only the most common mutation (if any) for each site 268 (Supplemental figure 2). Taking these sites in aggregate will give a combination of true 269 mutations as well as other sources of error, most notably sequencing error. Figure 4 shows 270 the sum of mutations over the whole genome for viruses propagated in 10 µM or 100 µM 271 favipiravir or for control viruses which were not exposed to favipiravir. Comparing the 272 pattern of mutations between the control viruses and the viruses exposed to drug allowed 273 us to control for sequencing errors. The pattern of mutations seen in both samples exposed In this study, we used two different methods of analysing next-generation sequencing data 291 in order to show that favipiravir acts as a mutagen with a distinct bias to induce transitions 292 in influenza virus RNAs. The first method used Primer ID to measure precisely the increase in 293 mutation rate and the mutation bias of the influenza polymerase caused by favipiravir in an 294 in vitro system. We confirmed that favipiravir has a bias for transition mutations and acts as 295 a purine analogue 17,26,32,33 . We were able to demonstrate that favipiravir competed 296 primarily with guanine and secondarily with adenine resulting in an increase in C->U and G-297 >A mutations at higher concentrations of drug and a lower rate of increase in U->C and A->G 298 mutations ( Figure 5 ). The second method used data from whole-genome sequencing of 299 viruses that had been exposed to favipiravir during single cycle replication and showed that 300 viral populations exposed to favipiravir had a distinct bias for transition mutations, accidentally counting an initial polymorphism in the population as a mutational event that 308 occurred in multiple clones. Sequencing a small region of the genome across many clones is 309 especially prone to this error. Next-generation sequencing with Primer ID is a powerful 310 technique which allowed us to examine orders of magnitude more mutations than Sanger 311 sequencing and was less prone to biases present in examining a small number of mutations. 312 Primer ID allowed us to remove sequencing error from next-generation sequencing data and 313 to detect changes in mutation rate and mutation bias 39, 40 . Primer ID identified thousands of 314 mutations in a single sample exposed to favipiravir, a number which would be impractical 315 using Sanger sequencing. We were able to show that favipiravir acts as both a guanine and 316 an adenine analogue whereas Sanger sequencing was not sensitive enough to measure the 317 lower rate of adenine mutations 27 . 318 The use of the minigenome assay allowed us to see all mutations generated by polymerase 319 and not just those that would allow viable viruses. Pauly et al. have recently shown that the 320 mutation rate for influenza has been significantly underestimated by only counting 321 mutations which occur in plaque forming viruses 47 . Sequencing only viruses which have 322 exited the cell ignores mutations that cause defects in packaging or cellular exit. By contrast, 323 as the mRNA from the reporter in the minigenome assay is not translated to a protein that 324 can impact on viral fitness, the full spectrum of drug-induced mutations can be seen. 325 Allowing for multiple rounds of virus replication makes it difficult to see strongly deleterious 326 mutations, which make up a significant proportion of the mutations for influenza, because 327 they are selected against 48 . The minigenome assay has no selection on mutations and does 328 not suffer from this bias. However, when we used a Primer ID approach to sequence a small 329 portion of the viral genome from PB1 amplified during virus infection rather than in the 330 minigenome assay, we found, contrary to the minigenome sequencing, that there was no 331 increase in the mutation rate at the highest concentrations of favipiravir. This is likely due to 332 selection against deleterious mutations that occurs even in a single cycle of replication. 333 Favipiravir causes mutations randomly and therefore there will be a distribution in the 334 number of mutations during each strand replication. Some RNAs will have many mutations 335 whereas others will have fewer. The majority of the RNA that was sequenced will come 336 from viruses which have suffered few mutations, as viral RNAs with more mutations will 337 interfere with ongoing replication. Therefore, the more successful favipiravir is at causing 338 mutations, the greater the bias to sequencing the small number of viruses with fewer 339 mutations. This most likely explains why the mutation rate we measured appeared lower at 340 100 µM favipiravir than at 10 µM. 341 Although Primer ID can remove sequencing error, it is still impossible to distinguish between 342 errors due to the flu polymerase and the reverse transcriptase used during the Primer ID 343 reaction. A recent paper has suggested that care must be taken as these two error rates are 344 the same order of magnitude 47 . For this reason, we have not reported an absolute error rate 345 but a relative error rate compared to the drug-free baseline sample. However, for our 346 experiments, the mutation rate caused by favipiravir was much higher than the calculated 347 baseline mutation rate caused by reverse transcription errors plus errors naturally caused by 348 the influenza polymerase. Furthermore, as all samples underwent identical processing, 349 there is no reason to believe that the error rate during reverse transcription differed 350 between samples and therefore, this is unlikely to bias our data. Care would need to be 351 taken before comparing samples which have not been prepared concurrently especially if 352 using different reverse transcription enzymes. One disadvantage to Primer ID is that it sequences only a small part of the genome. This 355 potentially could lead to mutation biases if that part of the genome was under strong 356 selection or due to local sequence structure. As we sampled only one region of the HA, we 357 could not test whether there were specific structural differences between the HA sequence 358 and other flu segments leading to mutational hotspots. However, the similarity between our 359 analysis of RNAs from primer ID vs whole genome sequencing suggests we did not 360 inadvertently sample a mutational hotspot. The precision and ease with which Primer ID 361 was able to distinguish mutation bias and observe changes in mutation rate leads us to 362 suggest that it could become a standard method for analysing the effects of nucleoside 363 analogues and other mutagenic drugs. 364 Our second method of analysis sequenced the whole flu genome in populations of viruses 365 that had been exposed to favipiravir and a control population that was not exposed to the 366 drug as might be found in a clinical setting. The main disadvantage of this technique is that it 367 is unable to distinguish between sequencing error and 'true' errors caused by the flu 368 polymerase. Therefore, it is not possible to quantify the actual number of errors due to 369 polymerase nor was the method sensitive enough to demonstrate any increase in the rate 370 of U->C and A->G mutations. Despite these limitations, there are several advantages to this 371 method that may prove to be of use in clinical settings. This method is extremely simple to 372 use as the viruses can be entered into the standard influenza sequencing pipeline without 373 any additional processing steps and could also be used to reanalyse data that had been 374 previously collected. The analysis also encompasses the whole genome and so is resistant to 375 any biases caused by local RNA structure nor is it biased by single polymorphisms that may 376 have been present in the initial populations. If favipiravir is used in a clinical setting, this 377 method may be a simple way to show that favipiravir is having a measurable effect by 378 comparing viral mutations in pre-treatment and post-treatment samples. 379 In contrast to our finding that favipiravir acts as a purine analogue, a previous study that to increased noise in the data but ensured that there was no bias towards pre-existing 391 polymorphisms or variations in sequencing depth. We also tested the mutational bias by 392 only counting the 500 sites with the largest degree of polymorphism (Supplemental figure 4) 393 which showed similar results to our main analysis though potentially with less noise. This 394 suggests that imposing a cut-off on variants will not bias the results if the sequencing 395 contains enough variants that positive selection and pre-existing polymorphisms are unlikely 396 to influence the results. 397 Our data showed that favipiravir acts as a mutagen with a bias towards transitions in 398 agreement with most other studies of this drug's effect on RNA viruses 27,28,35 . We found that 399 at lower concentrations of favipiravir, there was no evidence that the drug was acting as a 400 chain terminator as there was no reduction in the amount of mRNA despite a reduction in 401 reporter gene activity (Figure 2A, B) . At the highest concentration tested (100 µM), there 402 was a reduction in mRNA which could have been caused by chain termination or through 403 introduced mutations preventing RNA replication. The lack of evidence for chain 404 termination at lower concentrations of favipiravir suggests that favipiravir is primarily acting 405 as a mutagen. Biochemically, favipiravir acts as a purine analogue binding to either C or U in 406 place of G or A respectively. The most common mutations caused by favipiravir were C->U 407 and G->A. These mutations were caused by favipiravir binding to C in place of a G on the 408 positive or negative strand synthesis and subsequently pairing with a U in the next synthesis 409 cycle ( Figure 5 ). The reverse transitions caused by favipiravir binding to U happened at a 410 ~3.5-fold lower rate. This confirms that favipiravir is most competitive against G as had been 411 previously seen in primer extension assays 32, 33 . 412 Next-generation Sequencing is a powerful technique for analysing mutational data and 413 determining mutational biases. Care must be taken to perform analyses which minimize 414 potential biases by ensuring that mutations are only counted when they occur 415 independently of each other. We used NGS to show that favipiravir is acting as a mutagen 416 causing multiple additional mutations per influenza genome on average at higher 417 concentrations of favipiravir. Lethal mutagenesis of influenza is a viable antiviral strategy 418 and may be difficult to evolve resistance against clinically 49 . Our increased knowledge of the 419 precise mechanism of favipiravir means that we are better placed to test whether the drug 420 is having a clinical effect as well as to see whether viruses are becoming resistant to 421 favipiravir. This will be important when this drug is used in a pandemic situation. 422 partnership with Public Health England (PHE). PL, PK and WB were supported by Wellcome analogue. Virus was added to MDCK cells at a high MOI of 1 and drug was added as 584 previously described. Supernatant was taken and was sequenced and analysed as described 585 in Methods. The most common polymorphism for each base is shown for virus exposed to 586 drug and to a drug free control. The comparison shows the difference in percentage for 587 each class of mutations revealing mutation bias. TCGTTACTTTGGTC   TCTAGCCATGCCCGGCTTCGATCGTTACTTTGGTC  TTTAGCCATGCCCAGCTTCGATCGTTACTTTGGTC  TTTAGCCATGCCCAGCTTCGATCGTTACTTTGGTC  TTTGGCCATGCCCAGCTTCGATCGTTACTTTGGTC  TTTAGCCATGCCCAGCTTCGATCGTTACTTTGGTC  TTTAGGCATGCCCAACTTTGAATTATCCCTTGCTG  TTCAGCCATGCCCAACTTTGAATTATCCCTTGCTG  TTTACCCATGCCCAACTTTGAATTATCCCTTGCTG  TTTAGCCATGCCCAACTTTGAATTATCCCTTGCTG  TTTAGTCATGCTCAGCTTTGAAATATGTGATCTTC  TTTAGTTATGCTCAGTTTTGAAATATGTGATCTTC  TTTAGTCATGCTCAGCTTTGAAATATGTGATCTTC  TTTAGTCATGCTCAGCTTCGAAATATGTGATCTTC  TTTAGCCATGCCCAGGTTTGATGACTCACATGTGA  TTTAGCTATGCCCAGCTTTGATGACTCACATGTGA  TTTAGCCATGCCCAGCTTTGATGACTCACATGTGA 
